Results 31 to 40 of about 64,054 (239)

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

open access: yesFrontiers in Oncology
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1.
Céline Eldani   +22 more
doaj   +1 more source

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia

open access: yesScience Progress, 2021
Lay abstract Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia: Immune Checkpoint Inhibitors (ICIs) are rapidly growing and changing cancer care.
Mohammed Al Nuhait   +4 more
doaj   +1 more source

: A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature

open access: yesMedicine, 2022
Introduction: The indications for immune checkpoint inhibitors (ICIs) are expanding for various cancers because of their durable responses and tolerable safety profiles. Immune-related adverse events (irAEs), including neurological adverse events (nAEs), are associated with ICIs therapy.
Heesung Moon   +5 more
openaire   +3 more sources

IMMU-51. NEUROLOGIC IMMUNE-RELATED ADVERSE EVENTS MIMICS, RISK FACTORS, AND MECHANISMS: CLIPPERS AND ASEPTIC MENINGITIS [PDF]

open access: yesNeuro-Oncology, 2020
Abstract Neurological immune-related adverse events (irAEs) are rare toxicities that occur following immune checkpoint blockade. It is imperative to distinguish between irAEs and their mimics for successful treatment. We present the first case of CLIPPERS-like lesions in a patient with thymic cancer, thymoma, and a family history of ...
Carlen Yuen   +3 more
openaire   +1 more source

Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report

open access: yesFrontiers in Pharmacology, 2022
It is of great clinical value to investigate the immune-related adverse events (irAEs), especially demyelinating lesions, caused by immune checkpoint inhibitors (ICIs). The incidence of demyelinating lesions is less frequent in irAEs, but once it occurs,
Wenhui Liu   +12 more
doaj   +1 more source

The human gut microbiome across the life course

open access: yesFEBS Letters, EarlyView.
Despite significant individual variation and continuous change throughout life, the human gut microbiome follows some life stage‐specific trends. This article provides a brief overview of how gut microbiome composition shifts across different phases of life. Created in BioRender. Özkurt, E. (2026) https://BioRender.com/8q4nrnc.
Alise J. Ponsero   +4 more
wiley   +1 more source

Neurological complications of immune checkpoint inhibitor therapy: a multidisciplinary case review

open access: yesНеврология, нейропсихиатрия, психосоматика
Immunotherapy using immune checkpoint inhibitors (ICIs) has demonstrated efficacy in treating a wide range of oncological diseases, but the use of this group of drugs is associated with the risk of developing serious immune-related adverse events (irAEs).
I. Yu. Oganesyan   +8 more
doaj   +1 more source

Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data

open access: yesFrontiers in Oncology, 2022
Immune checkpoint inhibitors (ICIs) are widely used improving clinical outcomes in many cancer patients. However, they can induce serious consequences, like neurological immune-related adverse drug reactions (NirADRs).
Rosanna Ruggiero   +20 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database

open access: yesFrontiers in Immunology
BackgroundImmune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment. With the widespread use of ICIs, immune-related adverse events (irAEs) have increased gradually. Neurotoxicity, as an irAE,
Lin Cao, Yanfei Wang, Peng Dai, Xia Li
doaj   +1 more source

Home - About - Disclaimer - Privacy